

# **Treatment of Congenital Hemangiomas (Port Wine Stains)**

Policy MP-014

Origination Date: 07/24/2018

Reviewed/Revised: 10/25/2023

Next Review Date: 10/25/2024

Current Effective Date: 10/25/2023

#### Disclaimer:

- 1. Policies are subject to change in accordance with State and Federal notice requirements.
- 2. Policies outline coverage determinations for U of U Health Plans Commercial, CHIP and Healthy U (Medicaid) plans. Refer to the "Policy" section for more information.
- 3. Services requiring prior-authorization may not be covered, if prior-authorization is not obtained.
- 4. This Medical Policy does not guarantee coverage or payment of the service. The service must be a benefit in the member's plan and the member must be eligible for coverage at the time of service. Additional payment guidelines may be applied that are not included in this policy.

### **Description:**

Port wine stain (PWS), a congenital malformation, begins as a pale pink flat area (macular lesion) in childhood. As the patient ages, the stain grows commensurately. The abnormal blood vessels within the PWS become progressively more dilated in size which results in the lesion becoming dark purple and elevated in some instances. Nodules and hypertrophy may develop in the soft tissue underlying the PWS. Nodules may continue to grow and begin to bleed easily if traumatized.

Common areas for PWS to appear are on the face over the areas of the first and second trigeminal nerves and the eyes or mouth. Also, it is not uncommon to see a PWS overlying an arteriovenous, arterial or venous malformation. Port wine stains in these locations would require the physician to look beyond the skin for any underlying problem. Port wine stain has the distinction of persisting into adult life, and is associated with systemic abnormalities such as glaucoma.

Treatment of a PWS in its macular stage will prevent the development of the hypertrophic component of the lesion. Laser treatment of a PWS diminishes the existing blood vessels making them smaller and fewer in numbers. Therefore, the progression of these lesions to a more advanced size is less likely to occur.

## **Policy Statement and Criteria**

### 1. Commercial Plans/CHIP

U of U Health Plans covers laser treatment of port wine stains when the purpose of the treatment is to resolve the lesion in a potentially functionally important area *in limited circumstances*.

Areas considered of functional importance by the plan are as follows:

- A. The genitals.
- B. The facial triangle enclosed by the ears and the chin.
- C. Any port wine stain area to resolve a functional problem associated with pain, discomfort or bleeding.

U of U Health Plans does NOT cover laser treatment of port wine stains for cosmetic or psychological reasons. Use for cosmetic or psychological reasons falls under the plan's cosmetic exclusion of coverage.

### 2. Medicaid Plans

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the U of U Health Plans Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website at: <u>https://medicaid.utah.gov/utah-medicaid-official-publications/</u> or the <u>Utah Medicaid code Look-Up tool</u>

CPT/HCPCS codes covered by Utah State Medicaid may still require further evaluation to determine medical necessity for coverage.

### **Clinical Rationale**

The pulsed dye laser delivers energy at a wavelength and duration that has been optimized for the selective treatment of vascular lesions. It has been used in the treatment of warts, port wine stains, hemangiomas, hypertrophic scars, and telangiectasias. Pulsed dye lasers have been used as an alternative to surgical excision or carbon dioxide lasers.

The Food and Drug Administration (FDA) has cleared the pulsed-dye laser for use in treatment of warts, port-wine stains, hemangiomas, hypertrophic scars, and telangiectasias. The pulsed-dye laser has been shown to be effective in treating glomangiomas in the face and neck, as surgical excision may not be practical in these cosmetically sensitive areas. The pulsed-dye laser has also shown to be effective in removing pyogenic granulomas in cosmetically sensitive areas of the face and neck.

A 2018 study (Zhu et al) found that Port-wine stains (PWS) affect 0.3 to 0.5% of newborns and pulsed dye laser (PDL) remains the treatment of choice. This study is designed to evaluate whether more frequent PDL treatments in infantile patients would achieve further lightening of erythema. We prospectively investigated 20 infants with PWS. Two adjacent sites were both treated for a 12-week

duration and randomly allocated to be treated for seven sessions at 2-week intervals or three sessions at 6-week intervals. The efficacy outcome 2 months after the final treatment was determined by visual and chromameter evaluation. Sixteen patients completed the study with a total of 54 treatment sites. Similar results were observed in the two groups. The average blanching rates were 42.93% (SD = 27.92%) and 43.81% (SD = 32.80%) for PDL treatments with seven and three sessions, respectively (p = 0.374). Partial recovery from the laser treatment was more frequently observed and side effects were significantly higher at 2-week follow-ups (p < 0.001), resulting in a total of 3-13 weeks for skin recovery. More frequent PDL treatments do not necessarily increase efficacy in infantile PWS patients. Considering the potential risks and added costs, this practice may not be of benefit.

In a randomized comparison study (Yu et al, 2018), the efficacy and safety of double-pass pulsed dye laser (DWL) and single-pass PDL (SWL) in treating virgin port wine stain (PWS) were compared. The increase in the extent of vascular damage attributed to the use of double-pass techniques for PWS remains inconclusive. Twenty-one patients (11 flat PWS, 10 hypertrophic PWS) with untreated PWS underwent 3 treatments at 2-month intervals. Each PWS was divided into three treatment sites: SWL, DWL, and untreated control. Chromametric and visual evaluation of the efficacy and evaluation of side effects were conducted 3 months after final treatment. Biopsies were taken at the treated sites immediately post treatment. Chromametric and visual evaluation suggested that DWL sites showed no significant improvement compared with SWL (p > 0.05) in treating PWS. The mean depth of photothermal damage to the vessels was limited to a maximum of 0.36-0.41 mm in both SWL and DWL sides. Permanent side effects were not observed in any patients. In conclusion, Double-pass PDL does not enhance PWS clearance. To improve the clearance of PWS lesions, either the depth of laser penetration should be increased or greater photothermal damage to vessels should be generated.

## **Applicable Coding**

### **CPT Codes**

17106	Destruction of cutaneous vascular proliferative lesions (eg, laser technique); less than 10 sq cm
17107	Destruction of cutaneous vascular proliferative lesions (eg, laser technique); 10.0 to 50.0 sq cm
17108	Destruction of cutaneous vascular proliferative lesions (eg, laser technique); over 50.0 sq cm

### **HCPCS** Codes

### No applicable codes

#### **References**:

- 1. Ashinoff, R. and Geronemus, R.G., 1991. Flashlamp-pumped pulsed dye laser for port-wine stains in infancy: earlier versus later treatment. Journal of the American Academy of Dermatology, 24(3), pp.467-472.
- 2. Brauer, J.A. and Geronemus, R.G., 2013. Laser treatment in the management of infantile hemangiomas and capillary vascular malformations. Techniques in vascular and interventional radiology, 16(1), pp.51-54.
- 3. Brightman, L.A., Geronemus, R.G. and Reddy, K.K., 2015. Laser treatment of port-wine stains. Clinical, cosmetic and investigational dermatology, 8, p.27.
- 4. Chowdhury MM, Harris S, Lanigan SW. Potassium titanyl phosphate laser treatment of resistant port-wine stains. Br J Derm 2001;144:814-17
- 5. Cordoro, K.M. and Frieden, I.J., 2010. Pulsed dye laser for port wine stains. Journal of the American Academy of Dermatology, 62(6), pp.1065-1066.

- 6. Enjolras O. Vascular malformations. In: Bolognia JL, Jorizzo JL, Rapini RP, senior editors. Horn TD, Mascaro JM, Saurat JH, Mancini AJ, Salasche SJ, Stingl G, editors. Dermatology. London: Mosby; 2003. p. 1615-29.
- 7. Food and Drug Administration (FDA), 510(k) #K033461, Premarket Notification 'Candela VBeam Pulse Dye Laser System" 2004.
- 8. Gupta G, Bilsland D. A prospective study of the impact of laser treatment on vascular lesions. Br J Derm 2000;143:356-59
- 9. Hohenleutner S, Badur-Ganter E, Landthaler M, et al. Long-term results in the treatment of childhood hemangioma with the flashlamp-pumped pulsed dye laser: An evaluation of 617 cases. Lasers Surg Med. 2001;28(3):273-277
- Izikson, L., Nelson, J.S. and Anderson, R.R., 2009. Treatment of hypertrophic and resistant port wine stains with a 755 nm laser: a case series of 20 patients. Lasers in Surgery and Medicine: The Official Journal of the American Society for Laser Medicine and Surgery, 41(6), pp.427-432.
- 11. Katugampola GA, Lanigan SW. Five years' experience of treating port wine stains with the flashlamp-pumped pulsed dye laser. Br J Dermatol. 1997;137(5):750-754.
- 12. McClean K, Hanke CW. The medical necessity for treatment of port-wine stains. Dermatol Surg. 1997;23(8):663-667.
- 13. Ortiz, A.E. and Nelson, J.S., 2012. Port-wine stain laser treatments and novel approaches. Facial plastic surgery: FPS, 28(6), pp.611-620.
- 14. Scherer K, Lorenz S, Wimmershoff M, et al. Both the flashlamp-pumped dye laser and the long-pulsed tunable dye laser can improve results in port-wine stain therapy. Br J Derm 2001;145:79-84
- 15. Shahriari, M., Makkar, H. and Finch, J., 2015. Laser therapy in dermatology: Kids are not just little people. Clinics in dermatology, 33(6), pp.681-686.
- 16. Stier, M.F., Glick, S.A. and Hirsch, R.J., 2008. Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas. Journal of the American Academy of Dermatology, 58(2), pp.261-285.
- 17. Updyke, K. M. and A. Khachemoune (2017). "Port-Wine Stains: A Focused Review on Their Management." J Drugs Dermatol 16(11): 1145-1151.
- UpToDate<sup>®</sup> (2022) "Capillary malformations (port wine stains) and associated syndromes". Literature current through: August 2022. Last topic update: March 24, 2022. Topic 13726. Version 27.0. Accessed September 2, 2022. Available at: www.uptodate.com
- 19. UpToDate<sup>®</sup> (2022) "Infantile hemangiomas: Management". Literature current through: August 2022. Last topic update: November 9, 2021. Topic 5792. Version 49.0. Accessed September 9, 2022. Available at: <u>www.uptodate.com</u>
- Van Raath, M.I., Chohan, S., Wolkerstorfer, A., Van der Horst, C.M.A.M., Storm, G. and Heger, M., 2019. Port wine stain treatment outcomes have not improved over the past three decades. Journal of the European Academy of Dermatology and Venereology, 33(7), pp.1369-1377.
- 21. Yu, W., et al. (2018). "Double Pass 595 nm Pulsed Dye Laser Does Not Enhance the Efficacy of Port Wine Stains Compared with Single Pass: A Randomized Comparison with Histological Examination." <u>Photomed Laser Surg</u>.
- 22. Yu, W., Ma, G., Qiu, Y., Chen, H., Jin, Y., Yang, X., Chang, L., Wang, T., Hu, X., Li, W. and Lin, X., 2015. Prospective comparison treatment of 595-nm pulsed-dye lasers for virgin port-wine stain. British Journal of Dermatology, 172(3), pp.684-691.
- 23. Zhu, J., et al. (2018). "Less is more: similar efficacy in three sessions and seven sessions of pulsed dye laser treatment in infantile port-wine stain patients." Lasers Med Sci.

#### Disclaimer:

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

U of U Health Plans makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. U of U Health Plans updates its Coverage Policies regularly, and reserves the right to amend these policies and give notice in accordance with State and Federal requirements.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from U of U Health Plans.

"University of Utah Health Plans" and its accompanying logo, and its accompanying marks are protected and registered trademarks of the provider of this Service and or University of Utah Health. Also, the content of this Service is proprietary and is

protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association